US biotech major Amgen (Nasdaq: AMGN) has entered into an agreement to acquire 100% of USA-based Catherex, a spin-out of Germany’s Medigene (DE: MDF1).
As a main shareholder of Catherex, Medigene Inc USA is entitled to approximately 40% of payments to be made by Amgen. The company was informed about the execution of the corresponding purchase agreement by Catherex, Amgen and the shareholders of Catherex. Medigene Inc USA is a 100% subsidiary of Medigene AG.
Deal involves $10.5 million upfront payment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze